MTNB Matinas BioPharma Holdings,...

NYSE matinasbiopharma.com


$ 0.59 $ 0.02 (3.4 %)    

Tuesday, 18-Feb-2025 17:00:04 EST
QQQ na $ -0.98 (-0.18 %)
DIA na $ 0.13 (0.03 %)
SPY na $ 1.79 (0.29 %)
TLT na $ -1.05 (-1.18 %)
GLD na $ 4.36 (1.64 %)
$ 0.6
$ 0.61
-- x --
-- x --
$ 0.59 - $ 0.61
$ 0.48 - $ 21.50
1,100,366
na
3.1M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2024 09-30-2024 10-Q
2 08-14-2024 06-30-2024 10-Q
3 05-09-2024 03-31-2024 10-Q
4 03-27-2024 12-31-2023 10-K
5 11-08-2023 09-30-2023 10-Q
6 08-09-2023 06-30-2023 10-Q
7 05-10-2023 03-31-2023 10-Q
8 03-15-2023 12-31-2022 10-K
9 11-02-2022 09-30-2022 10-Q
10 08-11-2022 06-30-2022 10-Q
11 05-12-2022 03-31-2022 10-Q
12 03-08-2022 12-31-2021 10-K
13 11-08-2021 09-30-2021 10-Q
14 08-10-2021 06-30-2021 10-Q
15 05-10-2021 03-31-2021 10-Q
16 03-29-2021 12-31-2020 10-K
17 11-06-2020 09-30-2020 10-Q
18 08-10-2020 06-30-2020 10-Q
19 05-11-2020 03-31-2020 10-Q
20 03-09-2020 12-31-2019 10-K
21 11-13-2019 09-30-2019 10-Q
22 08-13-2019 06-30-2019 10-Q
23 05-13-2019 03-31-2019 10-Q
24 04-01-2019 12-31-2018 10-K
25 11-09-2018 09-30-2018 10-Q
26 08-09-2018 06-30-2018 10-Q
27 05-09-2018 03-31-2018 10-Q
28 03-16-2018 12-31-2017 10-K
29 11-14-2017 09-30-2017 10-Q
30 08-08-2017 06-30-2017 10-Q
31 05-15-2017 03-31-2017 10-Q
32 03-31-2017 12-31-2016 10-K
33 11-14-2016 09-30-2016 10-Q
34 08-15-2016 06-30-2016 10-Q
35 05-13-2016 03-31-2016 10-Q
36 03-30-2016 12-31-2015 10-K
37 11-10-2015 09-30-2015 10-Q
38 08-13-2015 06-30-2015 10-Q
39 05-15-2015 03-31-2015 10-Q
40 03-31-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 111-equity-group-increases-stake-to-517-in-matinas-biopharma-as-strategic-review-underway-including-asset-sale-of-mat2203-103m-cash-reported-which-would-equate-to-roughly-213-cash-per-share-value

111 Equity Group, LLC ("111 Equity") and its principal filed a Schedule 13D with the Securities and Exchange Commission...

 matinas-biopharma-receives-nyse-noncompliance-notice

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicati...

 maxim-group-downgrades-matinas-biopharma-hldgs-to-hold

Maxim Group analyst Jason McCarthy downgrades Matinas BioPharma Hldgs (AMEX:MTNB) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION